Edition:
India

CRISPR Therapeutics AG (CRSP.OQ)

CRSP.OQ on NASDAQ Stock Exchange Global Market

33.75USD
22 Jan 2018
Change (% chg)

$4.02 (+13.52%)
Prev Close
$29.73
Open
$31.00
Day's High
$34.18
Day's Low
$30.76
Volume
242,032
Avg. Vol
113,384
52-wk High
$34.18
52-wk Low
$11.74

Select another date:

Fri, Jan 5 2018

BRIEF-Crispr Therapeutics Says Public Offering Of 5 Mln Common Shares Priced At $22.75/Share

* CRISPR THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON SHARES

BRIEF-Crispr Therapeutics ‍Commences Public Offering Of $100 Mln Common Shares​

* CRISPR THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES

BRIEF-Vertex, CRISPR Therapeutics To Co-Develop CTX001 As CRISPR/Cas9 Gene Edited Treatment

* VERTEX AND CRISPR THERAPEUTICS TO CO-DEVELOP AND CO-COMMERCIALIZE CTX001 AS CRISPR/CAS9 GENE EDITED TREATMENT FOR SICKLE CELL DISEASE AND Β-THALASSEMIA

BRIEF-CRISPR Therapeutics appoints Michael Tomsicek as CFO

* CRISPR Therapeutics announces appointment of Michael Tomsicek as Chief Financial Officer

BRIEF-CRISPR and Casebia collaborate with CureVac on mRNA for gene-editing programs

* CRISPR Therapeutics and Casebia collaborate with CureVac on mRNA for gene-editing programs

BRIEF-Crispr Therapeutics files for mixed shelf offering of up to $300 mln - SEC filing‍​

* Crispr Therapeutics AG - files for mixed shelf offering of up to $300 million - SEC filing‍​ Source text: (http://bit.ly/2jeQFaT) Further company coverage:

BRIEF-CRISPR Therapeutics announces third quarter results

* CRISPR Therapeutics announces third quarter 2017 financial results and provides business update

BRIEF-Merck KGaA: Canadian patent office to grant patent application for CRISPR technology

* MERCK KGAA - CANADIAN PATENT OFFICE TO GRANT MERCK KGAA, DARMSTADT, GERMANY'S PATENT APPLICATION FOR CRISPR TECHNOLOGY

BRIEF-CRISPR Therapeutics promotes Samarth Kulkarni to CEO

* CRISPR Therapeutics announces promotion of Samarth Kulkarni, Ph.D. to chief executive officer

BRIEF-Crispr Therapeutics Ag qtrly ‍net loss per share attributable to common shareholders $0.56​

* Crispr Therapeutics announces second quarter 2017 financial results and provides business update

Select another date: